Nursing Interventions and Supportive Care for the Prevention and Treatment of Oral Mucositis Associated with Cancer Treatment

ONF 2007, 31(4), 13-23. DOI: 10.1188/04.ONF.S4.13-23
Purpose/Objectives: To review novel approaches to assessing and managing patients with cancer who are at risk for oral mucositis.

Jump to a section

    References

    Adamietz, I.A., Rahn, R., Bottcher, H.D., Schafer, V., Reimer, K., & Fleischer, W. (1998). Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Supportive Care in Cancer, 6, 373-377.
    Beck, S.L. (1999). Mucositis. In C.H. Yarbo, M.H. Frogge, & M. Goodman (Eds.), Cancer symptom management (2nd ed., pp. 328-343). Sudbury, MA: Jones and Bartlett.
    Bellm, L.A., Cunningham, G., Durnell, L., Eilers, J., Epstein, J.B., Fleming, T., et al. (2002). Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board. Cancer Investigation, 20, 793-800.
    Berger, A., Henderson, M., Nadoolman, W., Duffy, V., Cooper, D., Saberski, L., et al. (1995). Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy. Journal of Pain and Symptom Management, 10, 243-248.
    Borbasi, S., Cameron, K., Quested, B., Olver, I., To, B., & Evans, D. (2002). More than a sore mouth: Patients' experience of oral mucositis. Oncology Nursing Forum, 29, 1051-1057.
    Buntzel, J., Glatzel, M., Kuttner, K., Weinaug, R., & Frohlich, D. (2002). Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology, 12(1, Suppl. 1), 4-13.
    Cerchietti, L.C., Navigante, A.H., Bonomi, M.R., Zaderajko, M.A., Menendez, P.R., Pogany, C.E., et al. (2002). Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer, 95, 2230-2236.
    Clarkson, J.E., Worthington, H.V., & Eden, O.B. (2003). Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database System Review, 3, CD000978.
    Dodd, M.J., Dibble, S., Miaskowski, C., Paul, S., Cho, M., MacPhail, L., et al. (2001). A comparison of the affective state and quality of life of chemotherapy patients who do and do not develop chemotherapy-induced oral mucositis. Journal of Pain and Symptom Management, 21, 498-505.
    Dodd, M.J., Larson, P.J., Dibble, S.L., Miaskowski, C., Greenspan, D., MacPhail, L., et al. (1996). Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncology Nursing Forum, 23, 921-927.
    Dodd, M.J., Miaskowski, C., Greenspan, D., MacPhail, L., Shih, A.S., Shiba, G., et al. (2003). Radiation-induced mucositis: A randomized clinical trial of micronized sucralfate versus salt and soda mouthwashes. Cancer Investigation, 21, 21-33.
    Dodd, M.J., Miaskowski, C., & Paul, S.M. (2001). Symptom clusters and their effect on the functional status of patients with cancer. Oncology Nursing Forum, 28, 465-470.
    Dorr, W., Spekl, K., & Farrell, C.L. (2002). Amelioration of acute oral mucositis by keratinocyte growth factor: Fractionated irradiation. International Journal of Radiation Oncology, Biology, Physics, 54, 245-251.
    Eilers, J. (2001). When the mouth tells us more than it says—The impact of mucositis on quality of life. Oncology Supportive Care Quarterly, 1(4), 31-42.
    Endo Pharmaceuticals, Inc. Data on file. (2003).
    Epstein, J.B., Silverman, S., Jr., Paggiarino, D.A., Crockett, S., Schubert, M.M., Senzer, N.N., et al. (2001). Benzydamine HC1 for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer, 92, 875-885.
    Foncuberta, M.C., Cagnoni, P.J., Brandts, C.H., Mandanas, R., Fields, K., Derigs, H.G., et al. (2001). Topical transforming growth factor-b3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy, 24, 384-388.
    Goldberg, S.L. (2003a June). Results of apilot study to evaluate the efficacy of EN3247 in the prevention of oral mucositis. Paper presented at the annual meeting of the Multinational Association of Supportive Care in Cancer, Berlin, Germany.
    Goldberg, S.L. (2003b, June). Safety and tolerability of EN3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: Results of a randomized, double-blind, placebo-controlled trial. Paper presented at the annual meeting of the American Society of Clinical Oncology, Chicago, IL.
    Goldberg, S.L., Piniero, L., Schuster, M.W., Coleman, M., McCarthy, P.L., Fruchtman, S.M., et al. (2002, February). Prevention of mucositis by EN3247 (Immunol) oral rinse: Final results of a randomized, vehicle-controlled study. Paper presented at the annual meeting of the American Society for Blood Marrow Transplantation and the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry, Orlando, FL.
    Knox, J.J., Puodziunas, A.L.V., & Feld, R. (2000). Chemotherapy-induced oral mucositis. Prevention and management. Drugs and Aging, 17, 257-267.
    Kostler, W.J., Hejna, M., Wenzel, C., & Zielinski, C.C. (2001). Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment. CA: A Cancer Journal for Clinicians, 51, 290-315.
    Larson, P.J., Miaskowski, C., MacPhail, L., Dodd, M.J., Greenspan, D., Dibble, S.L., et al. (1998). The PRO-SELF® Mouth Aware program: An effective approach for reducing chemotherapy-induced mucositis. Cancer Nursing, 21, 263-268.
    Mantovani, G., Massa, E., Astara, G., Murgia, V., Gramignano, G., Lusso, M.R., et al. (2003). Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs. Oncology Reports, 10, 197-206.
    McGuire, D.B. (2003). Barriers and strategies in implementation of oral care standards for cancer patients. Supportive Care in Cancer, 11, 435-441.
    Meropol, N.J., Somer, R.A., Gutheil, J., Pelley, R.J., Modiano, M.R., Rowinsky, E.K., et al. (2003). Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant. Journal of Clinical Oncology, 21, 1452-1458.
    Miller, M., & Kearney, N. (2001). Oral care for patients with cancer: A review of the literature. Cancer Nursing, 24, 241-54.
    Mueller, B.A., Millheim, E.T., Farrington, E.A., Brusko, C., & Wiser, T.H. (1995). Mucositis management practices for hospitalized patients: National survey results. Journal of Pain and Symptom Management, 10, 510-520.
    National Cancer Institute. (2003). Oral complications of chemotherapy and head/neck radiation. Retrieved October 6, 2003, from http://www.cancer.gov/cancerinfo/pdq/supportivecare/oralcomplications/HealthProfessional
    National Institutes of Dental and Craniofacial Research. (2002). Periodontal (gum) diseases. Retrieved December 11, 2002, from http://www.nider.nih.gov/scripts/pf.asp?ref=http://www.nicdr.nih.gov/health/newsandhealth
    Okuno, S.H., Woodhouse, C.O., Loprinzi, C.L., Sloan, J.A., LaVasseur, B.I., Clemens-Schutjer, D., et al. (1999). Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology, 22, 258-261.
    Peterson, D.E., & Petit, R.G. (2003, June). Phase III study: AES-14 in chemotherapy patients at risk for mucositis. Paper presented at the annual meeting of the American Society of Clinical Oncology, Chicago, IL.
    Redding, S.W., & Haveman, C.W. (1999). Treating the discomfort of oral ulceration resulting from cancer chemotherapy. Compendium of Continuing Education in Dentistry, 20, 389-392, 394, 396.
    Saarilahti, K., Kajanti, M., Joensuu, T., Kouri, M., & Joensuu, H. (2002). Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouth washes in the prevention of radiation-induced mucositis: A double-blind prospective randomized phase III study. International Journal of Radiation Oncology, Biology, Physics, 54, 479-485.
    Sadler, G.R., Stoudt, A., Fullerton, J.T., Oberle-Edwards, L.K., Nguyen, Q., & Epstein, J.B. (2003). Managing the oral sequelae of cancer therapy. Medsurg Nursing, 12(1), 28-36.
    Shih, A., Miaskowski, C., Dodd, M.J., Stotts, N.A., & MacPhail, L. (2002). A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncology Nursing Forum, 29, 1063-1080.
    Smith, T. (2001). Gelclair: Managing the symptoms of oral mucositis. Hospital Medicine, 62, 623-626.
    Sonis, S.T. (2003, June). The pathobiology of mucositis. Paper presented at the annual meeting of the American Society of Clinical Oncology, Chicago, IL.
    Spielberger, R., Emmanouilides, C., Stiff, P., Bensinger, T., Gentile, D., Weisdorf, T., et al. (2003, June). Use of recombinant human keratinocyte growth factor (rHuKGF) can reduce severe oral mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning—Results of a phase 3 trial. Paper presented at the annual meeting of the American Society of Clinical Oncology, Chicago, IL.
    Sprinzl, G.M., Galvan, O., de Vries, A., Ulmer, H., Gunkel, A.R., Lukas, P., et al. (2001). Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. European Journal of Cancer, 37, 2003-2009.
    Steele, V.E., Holmes, C.A., Hawk, E.T., Kopelovich, L., Lubet, R.A., Crowell, J.A., et al. (1999). Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiology, Biomarkers and Prevention, 8, 467-483.
    Stricker, C.T., & Sullivan, J. (2003). Evidence-based oncology oral care clinical practice guidelines: Development, implementation, and evaluation. Clinical Journal of Oncology Nursing, 7, 222-227.
    Subongkot, S., Frame, D., Leslie, W., & Drajer, D. (2003). Selective cyclo-oxygenase-2 inhibition: A target in cancer prevention and treatment. Pharmacotherapy, 23(1), 9-28.
    Valcarcel, D., Sanz, M.A., Jr., Sureda, A., Sala, M., Munoz, L., Subira, M., et al. (2002). Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation, 29, 783-787.
    Van der Rijt, C.C.D., & van Zuijlen, L. (2002). Studies on supportive care in oral mucositis: Random or randomized? European Journal of Cancer, 37, 1971-1973.
    Wilkes, J.D. (1998). Prevention and treatment of oral mucositis following cancer chemotherapy. Seminars in Oncology, 25, 538-551.
    Yamamura, K., Ohta, S., Yano, K., Yotsuyanagi, T., Okamura, T., & Nabeshima, T. (1998). Oral mucosal adhesive film containing local anesthetics: In vitro and clinical evaluation. Journal of Biomedical Materials Research, 43, 313-317.
    Yeager, K.A., Webster, J., Crain, M., Kasow, J., McGuire, D.B. (2000). Implementation of an oral care standard for leukemia and transplantation patients. Cancer Nursing, 23, 40-47.